S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
Log in

NASDAQ:LMNXLuminex Stock Price, Forecast & News

$32.06
-1.06 (-3.20 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$31.91
Now: $32.06▼
$33.77
50-Day Range
$28.50
MA: $33.55▼
$40.50
52-Week Range
$17.34
Now: $32.06▼
$41.69
Volume908,738 shs
Average Volume643,085 shs
Market Capitalization$1.47 billion
P/E Ratio139.40
Dividend Yield1.09%
Beta0.71
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market. The company also provides MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; TDAS, an analysis program designed for development and optimization of nucleic acid assays; IDEAS, an image analysis software; and xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism. In addition, it offers MultiCode assays and products comprising HSV 1&2 assays, and other products to detect infectious agents in clinical samples; ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 assays, ARIES FLU A/B and RSV assays, ARIES group A strep assays, ARIES bordetella assays, ARIES GBS assay, and ARIES C. difficile assays; and VERIGENE test cartridges, as well as operates as an original equipment manufacturer of custom reagents and instrumentation. The company serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is based in Austin, Texas.
Read More
Luminex logo

Beat the Market (BTM) Rank™

Analyst Opinion: 1.0Community Rank: 2.0Dividend Strength: 0.8Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.34 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:LMNX
Previous Symbol
CUSIP55027E10
CIK1033905
Webwww.luminexcorp.com
Phone512-219-8020

Debt

Debt-to-Equity Ratio0.42
Current Ratio7.25
Quick Ratio2.40

Price-To-Earnings

Trailing P/E Ratio139.40
Forward P/E Ratio128.24
P/E GrowthN/A

Sales & Book Value

Annual Sales$334.64 million
Price / Sales4.39
Cash Flow$0.34 per share
Price / Cash Flow94.76
Book Value$11.01 per share
Price / Book2.91

Profitability

EPS (Most Recent Fiscal Year)($0.21)
Net Income$-3,840,000.00
Net Margins3.04%
Return on Equity2.38%
Return on Assets1.87%

Miscellaneous

Employees1,247
Outstanding Shares45,790,000
Market Cap$1.47 billion
Next Earnings Date11/2/2020 (Estimated)
OptionableOptionable
$32.06
-1.06 (-3.20 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LMNX News and Ratings via Email

Sign-up to receive the latest news and ratings for LMNX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Luminex (NASDAQ:LMNX) Frequently Asked Questions

How has Luminex's stock been impacted by COVID-19 (Coronavirus)?

Luminex's stock was trading at $27.11 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, LMNX shares have increased by 18.3% and is now trading at $32.06.
View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Luminex?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last year. There are currently 1 sell rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Luminex.

When is Luminex's next earnings date?

Luminex is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Luminex.

How were Luminex's earnings last quarter?

Luminex Co. (NASDAQ:LMNX) issued its quarterly earnings results on Tuesday, August, 4th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.08 by $0.19. The medical instruments supplier had revenue of $109.52 million for the quarter, compared to analysts' expectations of $107.33 million. Luminex had a net margin of 3.04% and a return on equity of 2.38%. The firm's revenue for the quarter was up 31.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.11) EPS.
View Luminex's earnings history.

How often does Luminex pay dividends? What is the dividend yield for Luminex?

Luminex announced a quarterly dividend on Tuesday, May 26th. Investors of record on Thursday, June 18th will be given a dividend of $0.09 per share on Thursday, July 9th. This represents a $0.36 dividend on an annualized basis and a dividend yield of 1.12%. The ex-dividend date is Wednesday, June 17th.
View Luminex's dividend history.

What guidance has Luminex issued on next quarter's earnings?

Luminex issued an update on its third quarter 2020 After-Hours earnings guidance on Tuesday, August, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $100 million, compared to the consensus revenue estimate of $89.47 million.

What price target have analysts set for LMNX?

2 brokerages have issued 1 year price objectives for Luminex's stock. Their forecasts range from $21.00 to $32.00. On average, they anticipate Luminex's share price to reach $26.50 in the next year. This suggests that the stock has a possible downside of 17.3%.
View analysts' price targets for Luminex.

Has Luminex been receiving favorable news coverage?

News headlines about LMNX stock have trended very positive recently, according to InfoTrie. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Luminex earned a daily sentiment score of 4.0 on InfoTrie's scale. They also assigned media headlines about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term.
View the latest news about Luminex.

Who are some of Luminex's key competitors?

Some companies that are related to Luminex include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), Waters (WAT), Charles River Laboratories Intl. (CRL), BIO-TECHNE (TECH), Bruker (BRKR), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD).
View all competitors.

What other stocks do shareholders of Luminex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Luminex investors own include Baidu (BIDU), NVIDIA (NVDA), Crispr Therapeutics (CRSP), Cisco Systems (CSCO), Inovio Pharmaceuticals (INO), Square (SQ), Verizon Communications (VZ), AbbVie (ABBV), American Express (AXP) and Micron Technology (MU).

Who are Luminex's key executives?

Luminex's management team includes the following people:
  • Mr. Nachum Shamir, CEO, Pres & Director (Age 65)
  • Mr. Harriss T. Currie, CFO, Sr. VP of Fin. & Treasurer (Age 57)
  • Mr. Richard W. Rew II, Sr. VP, Gen. Counsel & Corp. Sec. (Age 51)
  • Mr. Todd C. Bennett, Sr. VP of Global Sales & Customer Operations (Age 49)
  • Mr. Randall J. Myers, Sr. VP of Global Manufacturing & Quality (Age 57)

What is Luminex's stock symbol?

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

Who are Luminex's major shareholders?

Luminex's stock is owned by many different institutional and retail investors. Top institutional shareholders include Copeland Capital Management LLC (1.83%), Principal Financial Group Inc. (0.78%), Cowen Prime Services LLC (0.37%), Russell Investments Group Ltd. (0.37%), Robeco Institutional Asset Management B.V. (0.30%) and Envestnet Asset Management Inc. (0.23%). Company insiders that own Luminex stock include Charles J Collins, G Walter Loewenbaum II, Nachum Shamir, Nancy Fairchild, Randall Myers and Richard W Rew II.
View institutional ownership trends for Luminex.

Which institutional investors are selling Luminex stock?

LMNX stock was sold by a variety of institutional investors in the last quarter, including Great Lakes Advisors LLC, Cowen Prime Services LLC, Bridge City Capital LLC, Dupont Capital Management Corp, UBS Group AG, Fisher Asset Management LLC, US Bancorp DE, and Mitsubishi UFJ Kokusai Asset Management Co. Ltd.. Company insiders that have sold Luminex company stock in the last year include Charles J Collins, G Walter Loewenbaum II, Nachum Shamir, Nancy Fairchild, Randall Myers, and Richard W Rew II.
View insider buying and selling activity for Luminex.

Which institutional investors are buying Luminex stock?

LMNX stock was purchased by a variety of institutional investors in the last quarter, including Copeland Capital Management LLC, Robeco Institutional Asset Management B.V., Russell Investments Group Ltd., Assenagon Asset Management S.A., Mackay Shields LLC, Envestnet Asset Management Inc., Hussman Strategic Advisors Inc., and Strs Ohio. Company insiders that have bought Luminex stock in the last two years include G Walter Loewenbaum II, and Nachum Shamir.
View insider buying and selling activity for Luminex.

How do I buy shares of Luminex?

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Luminex's stock price today?

One share of LMNX stock can currently be purchased for approximately $32.06.

How big of a company is Luminex?

Luminex has a market capitalization of $1.47 billion and generates $334.64 million in revenue each year. The medical instruments supplier earns $-3,840,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Luminex employs 1,247 workers across the globe.

What is Luminex's official website?

The official website for Luminex is www.luminexcorp.com.

How can I contact Luminex?

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]uminexcorp.com.

This page was last updated on 8/7/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.